Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Advertisement

Advertisement




Nov
15
Today In Oncology
Pancreatic Cancer Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
SABR May Be Comparable to Surgery for Early-Stage NSCLC
MD Anderson Launches 2.5 Billion Philanthropic Campaign
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo